Generation Bio (NASDAQ:GBIO) Stock Rating Upgraded by Wall Street Zen

Generation Bio (NASDAQ:GBIO) was upgraded by research analysts at Wall Street Zen to a “sell” rating in a research report issued on Saturday.

GBIO has been the topic of a number of other reports. Wedbush set a $5.50 target price on Generation Bio and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price objective on shares of Generation Bio in a research report on Friday, November 7th. Zacks Research upgraded Generation Bio to a “hold” rating in a research report on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Generation Bio in a research note on Thursday, January 22nd. Finally, Citigroup reiterated a “market perform” rating on shares of Generation Bio in a research note on Wednesday, December 17th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Generation Bio currently has a consensus rating of “Hold” and an average target price of $8.88.

Generation Bio Price Performance

Shares of Generation Bio stock opened at $5.34 on Friday. The company has a market cap of $35.99 million, a PE ratio of -0.57 and a beta of 2.05. The firm has a fifty day moving average price of $5.53 and a two-hundred day moving average price of $5.62. Generation Bio has a fifty-two week low of $3.00 and a fifty-two week high of $8.20.

Institutional Trading of Generation Bio

A number of large investors have recently bought and sold shares of GBIO. AQR Capital Management LLC bought a new position in shares of Generation Bio during the first quarter valued at $36,000. Marshall Wace LLP acquired a new stake in shares of Generation Bio during the 2nd quarter worth about $37,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Generation Bio during the 2nd quarter worth about $47,000. Shay Capital LLC bought a new position in Generation Bio during the 3rd quarter valued at about $64,000. Finally, ADAR1 Capital Management LLC acquired a new position in Generation Bio in the third quarter valued at about $136,000. 95.22% of the stock is currently owned by institutional investors.

Generation Bio Company Profile

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.